Improved anti-tumor immunity and efficacy upon combination of the IDO1 inhibitor GDC-0919 with anti-PD-l1 blockade versus anti-PD-l1 alone in preclinical tumor models. Issue 2 (December 2015) - Spahn, Jessica; Peng, Jing; Lorenzana, Edward; Kan, David; Hunsaker, Thomas; Segal, Ehud; Mautino, Mario; Brincks, Erik; Pirzkall, Andrea; Kelley, Sean; Mahrus, Sami; Liu, Liling; et al.